Press Releases & News

LA JOLLA, Calif.--(BUSINESS WIRE)--Calidi Biotherapeutics, Inc., a clinical-stage biotechnology company at the forefront of stem cell-based delivery of oncolytic viruses, announced today that it has executed a license agreement with Northwestern University for the exclusive commercialization rights to the IND and data generated from Northwestern’s…

SAN DIEGO, CA - (BUSINESS WIRE) - Calidi Biotherapeutics, Inc., a clinical-stage biotechnology company at the forefront of stem cell-based delivery of oncolytic viruses, announced today its partnership with GenScript ProBio, the biopharmaceutical contract research organization (CRO) and contract development and manufacturing organization (CDMO) segment…

SAN DIEGO, CA - (BUSINESS WIRE) - Calidi Biotherapeutics, Inc., a clinical-stage biotechnology company at the forefront of oncolytic virus-based immunotherapies for cancer, announced today that it has been granted a new patent from the European Patent Office (EPO). European Patent Number 3209382, “Combination Immunotherapy…

SAN DIEGO, CA - (BUSINESS WIRE) - Calidi Biotherapeutics, Inc., a clinical-stage biotechnology company at the forefront of stem cell-based delivery of oncolytic viruses, announced today that the Investigational New Drug (IND) application submitted by its partner, Personalized Stem Cells, Inc. (PSC), has received FDA…

SAN DIEGO, CA - (BUSINESS WIRE) - Calidi Biotherapeutics, Inc., a clinical-stage biotechnology company at the forefront of oncolytic virus-based immunotherapies for cancer, announced today the appointment of veteran biotech executive and Chairman of FibroGen, Inc., Jim Schoeneck, to its Board of Directors. Throughout his…

SAN DIEGO, CA - (BUSINESS WIRE) - Calidi Biotherapeutics, Inc., a clinical-stage biotechnology company at the forefront of oncolytic virus-based immunotherapies for cancer, announced today that data from clinical studies on their oncolytic agent, CAL1 vaccinia virus, and stem cell delivery system will be presented…

Recently, Personalized Stem Cells (PSC) was asked by the White House Task Force to apply to the FDA for expedited review of their application for using stem cells to treat patients with COVID-19.  Stem cell therapy is a distinct approach that treats lung inflammation caused by…

SAN DIEGO– (BUSINESS WIRE)– Calidi Biotherapeutics, Inc. (“Calidi”), a clinical‐stage biotechnology company at the forefront of oncolytic virus-based immunotherapies for cancer, today announced the appointment of COL (retired) George E. Peoples, MD, FACS to its Scientific and Medical Advisory Board.   Dr. Peoples has served his…

SAN DIEGO– (BUSINESS WIRE)– Calidi Biotherapeutics, Inc. (“Calidi”), a clinical‐stage biotechnology company at the forefront of oncolytic virus-based immunotherapies for cancer, today announced the appointment of seasoned biotech executive, Heehyoung Lee, Managing Partner at LumeBio, to its board of directors. Dr. Lee brings over 15…

SAN DIEGO--(BUSINESS WIRE)--Calidi Biotherapeutics, Inc., a clinical‐stage immuno-oncology company at the forefront of cell-based oncolytic virus immunotherapies for cancer, presented pre-clinical data on their lead oncolytic virus candidate SNV1 (allogeneic adipose derived mesenchymal stem cells loaded with tumor selective CAL1 vaccinia virus) in a poster…